JPRN-UMIN000017053已完成1 期
Phase I study of tamibarotene for relapse or refractory pediatric solid tumor - TBT-PI
ational Cancer Center Hospital East Division of Pediatric Oncology0 个研究点目标入组 21 人开始时间: 2015年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 3years-old 至 30years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous or asynchronous(within 5 years)other cancer except carcinoma in situ or intramucosal carcinoma 2)Active infection requires systemic therapy 3)Any abnormalities in electrocardiogram tested within 28 days, which require intervention 4)Respiratory disorder requiring oxygen supply 5)Woman during pregnancy, or impossible to discontinue breast-feeding from within 1 month prior to enrollment to 2 years after the final dose of study treatment. Woman without intent to use birth control from within 1 month prior to enrollment to 2 years after the final dose of study treatment. Man without intent to use birth control from within 1 month prior to enrollment to 2 years after the final dose of study treatment. 6)Severe psychiatric disorder 7)Patients with history of allergy to tamibalotene 8)Patients with history of treatment with tamibarotene 9)In patients having a brain tumor or metastasis to brain, a symptom with the intracranial hypertension is poor in control 10)Patients otherwise considered ineligible for enrollment in the study by the investigator
研究者
相似试验
尚未招募
2 期
Phase IIa study of tamibarotene in patients with ADPKDAutosomal Dominant Polycystic Kidney DiseaseJPRN-jRCT2011230055Hayashi Ayuto70
已完成
2 期
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic SyndromeAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT02807558Syros Pharmaceuticals155
已完成
2 期
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APLAcute Promyelocytic LeukemiaNCT00520208CytRx15
进行中（未招募）
不适用
n estudio de fase II de tamibaroteno en pacientes con leucemia promielocítica aguda que hayan recibido terapia previa con ATRA y trióxido de arsénico (STAR-1) - STAR-1Pacientes adultos con recidiva de leucemia promielocítica aguda (LPA) o leucemia promielocítica aguda refractaria después de haber sido tratados con ácido trans retinóico total (ATRA) y trióxido de arsénico (ATO) (en combinación o secuencialmente).MedDRA version: 9.1Level: LLTClassification code 10001020Term: Acute promyelocytic leukemiaEUCTR2007-002183-99-ESINNOVIVE Pharmaceuticals50
进行中（未招募）
不适用
A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1) - STAR-1MedDRA version: 9.1Level: LLTClassification code 10001019Term: Acute promyelocytic leukaemiaAcute Promyelocytic LeukemiaEUCTR2007-002183-99-ITINNOVIVE PHARMACEUTICALS50